

loci, but the number of markers they had from previous genotyping maps was quite low. We were able to find more markers using RAD-Seq, enabling them to more accurately pin down the QTL important for breeding applications³. So even if you have some knowledge of the genome, it can be beneficial to consider a whole-genome scan.

Q. In addition to SNP discovery and genotyping, are there other applications where RAD-Seq is valuable?

RN: You can use RAD-Seq for any application that employs sequencing technology, so there's a huge range of applications where it can provide value. It can be used to facilitate *de novo* assembly in genomes or to perform linkage analysis such as a bulk segregant study. This is important in plant genomics, where breeders are interested in finding markers that co-associate with certain desirable phenotypes. They use those markers as a diagnostic to confirm that a particular variety of plant possesses a valuable trait, such as disease resistance.

RAD-Seq can be used to survey the population structure of a particular wild species and perform phylogenetics studies by constructing genetic or linkage maps that provide a portrait of recombination rate across the genome. It also can be used to perform linkage disequilibrium mapping or association mapping studies, or study epigenetics such as changes in methylation status across a genome.

"RAD-Seq GBS is particularly elegant because it whittles down the amount of the genome that you're querying. It allows you to interrogate a scalable number of loci."

Q. Can you reconstruct a genome using RAD-Seq?

RN: Yes, we can use RAD sequencing to perform what is called "local" *de novo* assembly. The goal is to construct a small sequence contig of 300–500 base pairs around a nuclease digestion site. This local assembly is possible because of the unique architecture of a RAD fragment, which consists of a 5' end anchored to the restriction enzyme site and a randomly sheared 3' end. Both the 5' and 3' ends have adapters. When you do a RAD preparation, you perform a size selection of the fragments that are produced and create a series of ostensibly overlapping fragments. By using paired-end Illumina sequencing, you can sequence 50–100 base pairs from the restriction enzyme cut site and 50–100 bp in the randomly sheared genomic region. When you get the RAD-Seq data back you can then assemble or "stitch" it together into a contiguous DNA sequence. From there, you can align the contig back to a reference genome from a related species or EST database. Eric's laboratory at the University of Oregon has also pioneered major improvements in this strategy that enable longer local assemblies, up to several kilobases in length⁴.

Q. Why is sequence data so much more valuable than array data?

RN: Sequence data is essentially future proof. Once you've identified a candidate marker using RAD-Seq, that bit of information is digital and can be integrated with any future genomics resources that are developed. You could look for epigenetic changes in the sequence data, see if it harbors a rare allele or a structural variant, align it to an assembled reference genome, or if you only have a transcript assembly, you can BLAST (Basic local alignment search tool) against that as well. Because the sequence is digital, you have an incredible array of options. That's the real advantage for any type of sequence-based technology over analog gel-based or even array-based approaches.

Q. How do you select the correct enzyme?

RN: We consult with the customer, evaluate how many markers they require, and assess the genetic diversity of the species they are studying. We look at the available sequence data for the species and run some in silico analyses on the sequence information to try to predict how many sites we might uncover. Then we select the particular restriction enzyme that is going to generate the results they need. We have worked with over 60 species, so often we have empirical knowledge of a particular genome, enabling us to accurately guide customers to the right enzyme and advise them about what to expect from the output that will be generated.

JB: Sometimes it takes a little bit of detective work to figure out the optimal solution. Certain enzymes are overkill for what a customer needs and you have to consider the cost benefit. If you choose a restriction enzyme that produces more fragments, it will cost more to perform the analysis. A customer's budget is an important parameter in selecting the right enzyme.

Q. How do you handle organisms with reference genomes versus those without reference genomes?

RN: One of the benefits of RAD-Seq is that it can be used for organisms where there is a lot of genomic information and for those that have never been sequenced. If there is a reference genome available, such as for rice, we can use our technology to sequence 1% of the genome, identify genetic variants, position them on the reference genome, and provide the marker and genetic information to our customer.

For an organism that does not have a reference genome, such as sunflower, we would generate the exact same content; there just wouldn't be a reference genome to determine the position of those markers. The nice thing about RAD-Seq is that the data is forward compatible. With the revolution in genomics that's going on right now, there will be reference genomes available in an increasing number of species. Once these are available, one will be able to pull out the RAD-Seq data and determine the physical marker positions.

Q. Why would a customer choose to have Floragenex perform their RAD-Seq analyses?

NL: We've worked with a variety of commercial customers as well as academics that often have experience with next-generation sequencing. Even so, they're looking for a turnkey solution and want the

